{"nctId":"NCT02038036","briefTitle":"Ruxolitinib Efficacy and Safety in Patients With HU Resistant or Intolerant Polycythemia Vera vs Best Available Therapy.","startDateStruct":{"date":"2014-03-25","type":"ACTUAL"},"conditions":["Polycythemia Vera"],"count":149,"armGroups":[{"label":"Ruxolitinib","type":"EXPERIMENTAL","interventionNames":["Drug: Ruxolitinib"]},{"label":"Best Available Therapy (BAT)","type":"ACTIVE_COMPARATOR","interventionNames":["Drug: Best Available Therapy"]}],"interventions":[{"name":"Best Available Therapy","otherNames":["BAT"]},{"name":"Ruxolitinib","otherNames":["INC424"]}],"eligibilityModule":{"eligibilityCriteria":"Inclusion Criteria:\n\nConfirmed diagnosis of PV according to the 2008 World Health Organization criteria, Non-palpable spleen, Phlebotomy dependent, Resistant to or intolerant of hydroxyurea, ECOG performance status of 0, 1 or 2.\n\nExclusion Criteria:\n\nInadequate liver or renal function, Significant bacterial, fungal, parasitic, or viral infection requiring treatment, Active malignancy within the past 5 years, excluding specific skin cancers, Previously received treatment with a JAK inhibitor, Being treated with any investigational agent, Women who are pregnant or nursing.\n\nOther inclusion/exclusion criteria apply.","healthyVolunteers":false,"sex":"ALL","minimumAge":"18 Years","stdAges":["ADULT","OLDER_ADULT"]},"locations":{"multicenter":true},"periods":[],"outcomeMeasures":[{"type":"PRIMARY","title":"Number of Participants Achieving Hematocrit (Hct) Control at Week 28","description":"Proportion of patients achieving Hct control at Week 28 was defined by the absence of phlebotomy eligibility starting at Week 8 and continuing through Week 28, with no more than one phlebotomy eligibility occurring post randomization and prior to Week 8.\n\nPhlebotomy eligibility was defined by:\n\n* Confirmed Hct \\> 45% that is at least 3 percentage points higher than the Hct obtained at Baseline Or\n* Confirmed Hct \\> 48% The confirmation occurred 2 to 14 days subsequent to the initial observation.","paramType":"COUNT_OF_PARTICIPANTS","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"46","spread":null},{"groupId":"OG001","value":"14","spread":null}]}]}]},{"type":"SECONDARY","title":"Number of Participants Achieving a Complete Hematological Remission at Week 28","description":"Proportion of patients achieving a complete hematological remission at Week 28 was defined by:\n\n* Hct control at Week 28 defined by the absence of phlebotomy eligibility starting at Week 8 and continuing through Week 28, with no more than one phlebotomy eligibility occurring post randomization and prior to Week 8, and\n* WBC \\< 10 x109/L at Week 28, and\n* Platelets ≤ 400 x 109/L at Week 28","paramType":"COUNT_OF_PARTICIPANTS","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"17","spread":null},{"groupId":"OG001","value":"4","spread":null}]}]}]},{"type":"SECONDARY","title":"Number of Participants Achieving a Hematocrit (Hct) Control at Week 52 and Week 80","description":"Proportion of patients achieving a Hct control at Week 52 was defined by the absence of phlebotomy eligibility starting at Week 8 and continuing through Week 52, and no more than one phlebotomy eligibility occurring post randomization and prior to Week 8\n\n\\- Endpoint for Week 80 was defined, similarly.","paramType":"COUNT_OF_PARTICIPANTS","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"44","spread":null},{"groupId":"OG001","value":"5","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"35","spread":null},{"groupId":"OG001","value":"2","spread":null}]}]}]},{"type":"SECONDARY","title":"Number of Participants Achieving a Complete Hematological Remission at Week 52 and Week 80","description":"Proportion of patients achieving a complete hematological remission at Week 52, was defined by:\n\n* Hct control at Week 52, as defined by the absence of phlebotomy eligibility starting at Week 8 and continuing through Week 52 with no more than one phlebotomy eligibility occurring post randomization and prior to Week 8, and\n* White Blood Count (WBC) \\< 10 x10\\^9/L at Week 52, and\n* Platelets ≤ 400 x 10\\^9/L at Week 52\n* Endpoint for Week 80 was defined, similarly.","paramType":"COUNT_OF_PARTICIPANTS","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"17","spread":null},{"groupId":"OG001","value":"3","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"18","spread":null},{"groupId":"OG001","value":"2","spread":null}]}]}]},{"type":"SECONDARY","title":"Number of Participants With Phlebotomies Over Time","description":"Phlebotomy eligibility was defined by Confirmed Hct \\> 45% that is at least 3 percentage points higher than the Hct obtained at Baseline Or Confirmed Hct \\> 48%. The confirmation occurred 2 to 14 days subsequent to the initial observation.","paramType":"COUNT_OF_PARTICIPANTS","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"12","spread":null},{"groupId":"OG001","value":"29","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"7","spread":null},{"groupId":"OG001","value":"17","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"4","spread":null},{"groupId":"OG001","value":"2","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0","spread":null},{"groupId":"OG001","value":"1","spread":null}]}]}]},{"type":"SECONDARY","title":"Change From Baseline in Hematocrit (Hct) at Each Visit","description":"Hematocrit is the volume percentage of red blood cells (RBC) in the blood.","paramType":"MEAN","dispersionType":"Standard Deviation","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-0.65","spread":"2.943"},{"groupId":"OG001","value":"1.25","spread":"2.994"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-1.22","spread":"3.634"},{"groupId":"OG001","value":"1.63","spread":"3.344"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-2.33","spread":"4.581"},{"groupId":"OG001","value":"1.70","spread":"3.485"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-3.25","spread":"4.179"},{"groupId":"OG001","value":"1.83","spread":"3.439"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-3.05","spread":"4.307"},{"groupId":"OG001","value":"1.45","spread":"3.984"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-2.85","spread":"4.094"},{"groupId":"OG001","value":"1.52","spread":"2.934"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-2.60","spread":"4.101"},{"groupId":"OG001","value":"2.09","spread":"3.852"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-2.77","spread":"4.538"},{"groupId":"OG001","value":"2.05","spread":"4.587"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-2.49","spread":"4.445"},{"groupId":"OG001","value":"1.68","spread":"4.854"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-3.06","spread":"4.573"},{"groupId":"OG001","value":"2.73","spread":"2.922"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-3.20","spread":"3.886"},{"groupId":"OG001","value":"0.62","spread":"4.436"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-2.91","spread":"4.203"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-3.19","spread":"4.314"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-2.86","spread":"4.540"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-3.13","spread":"4.263"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-3.50","spread":"3.463"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-3.54","spread":"4.005"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-3.57","spread":"4.477"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-2.94","spread":"4.428"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-3.36","spread":"4.515"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-3.23","spread":"4.150"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-3.55","spread":"4.413"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-3.31","spread":"4.621"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-3.45","spread":"4.053"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-2.93","spread":"3.799"}]}]}]},{"type":"SECONDARY","title":"Change From Baseline in Hematocrit (Hct) at Each Scheduled Visit After Crossover in Participants Randomized to BAT Who Cross Over to Ruxolitinib","description":"Hematocrit is the percentage of red blood cells (RBC) in the blood.","paramType":"MEAN","dispersionType":"Standard Deviation","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-2.44","spread":"3.394"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-4.24","spread":"5.322"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-5.73","spread":"6.597"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-6.27","spread":"7.101"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-5.76","spread":"6.563"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-5.29","spread":"6.518"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-6.04","spread":"5.825"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-6.06","spread":"6.301"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-5.91","spread":"6.399"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-7.06","spread":"6.051"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-6.16","spread":"6.247"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-6.79","spread":"6.046"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-6.21","spread":"6.599"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-7.04","spread":"6.103"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-7.41","spread":"6.812"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-7.00","spread":"6.310"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-7.06","spread":"7.000"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-7.44","spread":"7.426"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-7.51","spread":"7.298"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-7.16","spread":"5.331"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-7.09","spread":"5.742"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-6.95","spread":"5.936"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-7.51","spread":"5.880"}]}]}]},{"type":"SECONDARY","title":"Spleen Length by Visit","description":"Spleen length was assessed by manual palpation at every study visit.","paramType":"MEAN","dispersionType":"Standard Deviation","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"0.00","spread":"0.000"},{"groupId":"OG001","value":"0.04","spread":"0.351"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0.00","spread":"0.000"},{"groupId":"OG001","value":"0.01","spread":"0.119"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0.00","spread":"0.000"},{"groupId":"OG001","value":"0.01","spread":"0.120"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0.00","spread":"0.000"},{"groupId":"OG001","value":"0.23","spread":"1.010"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0.00","spread":"0.000"},{"groupId":"OG001","value":"0.13","spread":"0.716"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0.00","spread":"0.000"},{"groupId":"OG001","value":"0.09","spread":"0.555"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0.00","spread":"0.000"},{"groupId":"OG001","value":"0.20","spread":"0.909"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0.01","spread":"0.120"},{"groupId":"OG001","value":"0.52","spread":"1.473"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0.06","spread":"0.482"},{"groupId":"OG001","value":"0.07","spread":"0.258"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0.00","spread":"0.000"},{"groupId":"OG001","value":"0.00","spread":"0.000"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0.03","spread":"0.246"},{"groupId":"OG001","value":"0.00","spread":"0.000"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0.00","spread":"0.000"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0.05","spread":"0.378"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0.12","spread":"0.985"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0.18","spread":"1.162"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0.08","spread":"0.458"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0.05","spread":"0.372"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0.05","spread":"0.378"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0.05","spread":"0.381"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0.00","spread":"0.000"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0.00","spread":"0.000"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0.02","spread":"0.129"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0.00","spread":"0.000"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0.02","spread":"0.136"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0.10","spread":"0.617"}]}]}]},{"type":"SECONDARY","title":"Change From Baseline in Eastern Cooperative Oncology Group (ECOG) Performance Status to Week 28","description":"The ECOG scale of performance status described the level of functioning of participants in terms of their ability to care for themselves, daily activity, and physical ability. The ECOG performance was recorded as per ECOG performance status grades ranging from 0 (fully active, able to carry on all pre-disease performance without restriction) to 5 (dead).","paramType":"COUNT_OF_PARTICIPANTS","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"49","spread":null},{"groupId":"OG001","value":"17","spread":null}]},{"measurements":[{"groupId":"OG000","value":"2","spread":null},{"groupId":"OG001","value":"1","spread":null}]},{"measurements":[{"groupId":"OG000","value":"0","spread":null},{"groupId":"OG001","value":"0","spread":null}]},{"measurements":[{"groupId":"OG000","value":"0","spread":null},{"groupId":"OG001","value":"0","spread":null}]},{"measurements":[{"groupId":"OG000","value":"0","spread":null},{"groupId":"OG001","value":"0","spread":null}]},{"measurements":[{"groupId":"OG000","value":"2","spread":null},{"groupId":"OG001","value":"38","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"9","spread":null},{"groupId":"OG001","value":"1","spread":null}]},{"measurements":[{"groupId":"OG000","value":"10","spread":null},{"groupId":"OG001","value":"5","spread":null}]},{"measurements":[{"groupId":"OG000","value":"1","spread":null},{"groupId":"OG001","value":"0","spread":null}]},{"measurements":[{"groupId":"OG000","value":"0","spread":null},{"groupId":"OG001","value":"0","spread":null}]},{"measurements":[{"groupId":"OG000","value":"0","spread":null},{"groupId":"OG001","value":"0","spread":null}]},{"measurements":[{"groupId":"OG000","value":"1","spread":null},{"groupId":"OG001","value":"13","spread":null}]}]}]},{"type":"SECONDARY","title":"Number of Participants Achieving a Partial Remission Based on the European Leukemia Net (ELN) and International Working Group for Myelofibrosis Research and Treatment (IWG-MRT) Criteria at Week 28","description":"Proportion of patients achieving a partial remission at Week 28, based on the ELN and IWG-MRT criteria, as defined by:\n\n* Myeloproliferative Neoplasm Symptom Assessment Form Total Symptom Score (MPN-SAF TSS) score reduction of greater than or equal to 10 points from baseline to Week 28, and\n* Hct control defined by the absence of phlebotomy eligibility starting at Week 8 and continuing through Week 28, with no more than one phlebotomy eligibility occurring post randomization and prior to Week 8, and\n* WBC \\< 10 x10\\^9/L at Week 28, and\n* Platelets ≤ 400 x 10\\^9/L at Week 28, and\n* No palpable spleen at Week 28, and\n* No hemorrhagic or thrombotic events, and\n* No transformation into post-PV myelofibrosis, myelodysplastic syndrome (IWG-MRT criteria) or acute leukemia (WHO criteria).","paramType":"COUNT_OF_PARTICIPANTS","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"7","spread":null},{"groupId":"OG001","value":"0","spread":null}]}]}]},{"type":"SECONDARY","title":"Number of Participants Who Achieved Partial Remission Based on the European Leukemia Net (ELN) and International Working Group for Myelofibrosis Research and Treatment (IWG-MRT) Criteria at Week 52 and Week 80","description":"Proportion of patients who achieved partial remission at Week 52 based on the ELN and IWG-MRT criteria, as defined by:\n\n* MPN-SAF TSS score reduction of greater than or equal to 10 points from baseline to Week 52 and\n* Hct control defined by the absence of phlebotomy eligibility starting at Week 8 and continuing through Week 52 with no more than one phlebotomy eligibility occurring post randomization and prior to Week 8, and\n* WBC \\< 10 x109/L at Week 52 and\n* Platelets ≤ 400 x 109/L at Week 52 and\n* No palpable spleen at Week 52 and\n* No hemorrhagic or thrombotic events, and\n* No transformation into post-PV myelofibrosis, myelodysplastic syndrome (IWG-MRT criteria) or acute leukemia (WHO criteria).\n* Endpoint for Week 80 was defined, similarly.","paramType":"COUNT_OF_PARTICIPANTS","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"5","spread":null},{"groupId":"OG001","value":"0","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"4","spread":null},{"groupId":"OG001","value":"0","spread":null}]}]}]},{"type":"SECONDARY","title":"Number of Participants Achieving a Hematocrit (Hct) Control at Week 104, Week 156, Week 208 and Week 260.","description":"Proportion of patients achieving a Hct control at Week 104 as defined by the absence of phlebotomy eligibility starting at Week 8 and continuing through Week 104 and with no more than one phlebotomy eligibility occurring post randomization and prior to Week 8 Endpoint for Week 156, Week 208 and Week 260 were defined, similarly.","paramType":"COUNT_OF_PARTICIPANTS","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"9","spread":null}]},{"measurements":[{"groupId":"OG000","value":"25","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"9","spread":null}]},{"measurements":[{"groupId":"OG000","value":"21","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"7","spread":null}]},{"measurements":[{"groupId":"OG000","value":"18","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"4","spread":null}]},{"measurements":[{"groupId":"OG000","value":"12","spread":null}]}]}]},{"type":"SECONDARY","title":"Number of Participants Achieving a Complete Hematological Remission at Week 104, Week 156, Week 208 and Week 260","description":"Proportion of patients achieving a complete hematological remission at Week 104 as defined by Hct control defined by the absence of phlebotomy eligibility starting at Week 8 and continuing through Week 104, with no more than one phlebotomy eligibility occurring post randomization and prior to Week 8, and\n\n* WBC \\< 10 x10\\^9/L at Week 104, and\n* Platelets ≤ 400 x 10\\^9/L at Week 104 Endpoint for Week 156, Week 208 and Week 260 were defined, similarly.","paramType":"COUNT_OF_PARTICIPANTS","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"15","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"19","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"11","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"9","spread":null}]}]}]},{"type":"SECONDARY","title":"Number of Participants Who Achieved Partial Remission Based on the European Leukemia Net (ELN) and International Working Group for Myelofibrosis Research and Treatment (IWG-MRT) Criteria at Week 104, Week 156, Week 208 and Week 260.","description":"Proportion of patients who achieved partial remission at Week 104, based on the ELN and IWG-MRT criteria, as defined by:\n\n* MPN-SAF TSS score reduction of greater than or equal to 10 points from baseline to Week 104, and\n* Hct control defined by the absence of phlebotomy eligibility starting at Week 8 and continuing through Week 104, with no more than one phlebotomy eligibility occurring post-randomization and prior to Week 8, and\n* WBC \\< 10 x10\\^9/L at Week 104, and\n* Platelets ≤ 400 x 10\\^9/L at Week 104, and\n* No palpable spleen at Week 104, and\n* No hemorrhagic or thrombotic events, and\n* No transformation into post-PV myelofibrosis, myelodysplastic syndrome (IWG-MRT criteria) or acute leukemia (WHO criteria) Endpoint for Week 156, Week 208 and Week 260 are defined, similarly.","paramType":"COUNT_OF_PARTICIPANTS","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"4","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"9","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"4","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0","spread":null}]}]}]},{"type":"SECONDARY","title":"Number of Participants With Transformation Free Survival Events","description":"Transformation-free survival is defined as one of the following:\n\n1. Myelofibrosis (MF) as evidenced by bone marrow biopsy, or\n2. Acute leukemia as evidenced by bone marrow blast counts of at least 20%, or peripheral blast counts of at least 20% lasting at least 2 weeks.\n3. Death due to any cause during treatment period","paramType":"COUNT_OF_PARTICIPANTS","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"4","spread":null},{"groupId":"OG001","value":"3","spread":null}]}]}]},{"type":"SECONDARY","title":"Number of Participants With Overall Survival (OS) Events","description":"Overall survival (OS) event is defined as death due to any cause. OS events were counted in the BAT arm, irrespective of whether participants crossed over to receive ruxolitinib when the event occurred.","paramType":"COUNT_OF_PARTICIPANTS","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"3","spread":null},{"groupId":"OG001","value":"6","spread":null}]}]}]},{"type":"SECONDARY","title":"Change From Baseline in Myeloproliferative Neoplasm Symptom Assessment Form Total Symptom Score (MPN-SAF TSS)","description":"The MPN-SAF TSS is a disease specific questionnaire comprised of 10 items that measures fatigue related to MPN disease and the severity of nine of the most prevalent associated symptoms. Each item is scored on a scale ranging from 0 (no fatigue/absent) to 10 (As bad as you can imagine/worst imaginable).The MPN-SAF TSS is computed as the average of the observed items multiplied by 10 to achieve a 0-to-100 scale. The MPN-SAF TSS thus has a possible score range of 0 to 100 where a decrease indicates improvement.","paramType":"MEAN","dispersionType":"Standard Deviation","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-8.43","spread":"12.341"},{"groupId":"OG001","value":"0.40","spread":"12.586"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-9.86","spread":"12.210"},{"groupId":"OG001","value":"1.37","spread":"12.046"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-9.14","spread":"13.980"},{"groupId":"OG001","value":"1.41","spread":"10.760"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-10.29","spread":"14.204"},{"groupId":"OG001","value":"2.34","spread":"13.047"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-9.35","spread":"14.027"},{"groupId":"OG001","value":"0.10","spread":"9.586"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-8.63","spread":"13.403"},{"groupId":"OG001","value":"0.63","spread":"9.334"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-9.04","spread":"13.520"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-7.69","spread":"11.971"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-6.82","spread":"13.297"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-6.76","spread":"13.702"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-8.26","spread":"16.234"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-8.56","spread":"15.653"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-8.48","spread":"15.081"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-7.65","spread":"14.392"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-9.34","spread":"14.675"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-7.57","spread":"14.922"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-9.26","spread":"16.347"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-7.20","spread":"16.054"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-7.50","spread":"15.922"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-7.82","spread":"16.905"}]}]}]},{"type":"SECONDARY","title":"Change From Baseline in Total Scores of MPN-SAF by Visit in Patients From BAT Group Who Cross Over to Ruxolitinib After Crossover","description":"The MPN-SAF TSS is a disease specific questionnaire comprised of 10 items that measures fatigue related to MPN disease and the severity of nine of the most prevalent associated symptoms. Each item is scored on a scale ranging from 0 (no fatigue/absent) to 10 (As bad as you can imagine/worst imaginable).The MPN-SAF TSS is computed as the average of the observed items multiplied by 10 to achieve a 0-to-100 scale. The MPN-SAF TSS thus has a possible score range of 0 to 100 where a decrease indicates improvement.","paramType":"MEAN","dispersionType":"Standard Deviation","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-8.00","spread":"10.532"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-9.76","spread":"11.543"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-9.40","spread":"12.040"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-9.15","spread":"12.738"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-8.46","spread":"12.212"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-8.58","spread":"13.302"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-7.15","spread":"14.392"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-10.49","spread":"13.902"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-8.08","spread":"16.288"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-9.01","spread":"14.708"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-10.18","spread":"15.740"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-8.36","spread":"17.030"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-9.54","spread":"14.573"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-11.15","spread":"14.305"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-10.13","spread":"16.113"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-10.88","spread":"14.357"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-9.43","spread":"15.360"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-10.02","spread":"15.986"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-8.01","spread":"14.404"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-9.84","spread":"14.979"}]}]}]},{"type":"SECONDARY","title":"Change From Baseline in Score as Per European Quality of Life 5-Dimension 5-level (EQ-5D-5L) Questionnaire","description":"EQ-5D-5L is a standardized instrument for measuring health outcomes in a wide range of health conditions and treatments. It consists of visual analogue scale (EQ VAS) which records the respondent's self-rated health on a vertical, visual analogue scale where the endpoints are labeled 'Best imaginable health state' and 'worst imaginable health state'. The EQ VAS scores were anchored on 100 = the best health you can imagine and 0 = worst health you can imagine.","paramType":"MEAN","dispersionType":"Standard Deviation","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"4.24","spread":"11.661"},{"groupId":"OG001","value":"0.04","spread":"18.323"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"7.62","spread":"14.846"},{"groupId":"OG001","value":"-2.73","spread":"16.097"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"6.35","spread":"17.946"},{"groupId":"OG001","value":"-3.12","spread":"14.435"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"7.56","spread":"14.309"},{"groupId":"OG001","value":"0.16","spread":"15.201"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"7.36","spread":"13.996"},{"groupId":"OG001","value":"2.50","spread":"10.697"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"4.50","spread":"18.273"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"6.77","spread":"18.948"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"6.25","spread":"18.143"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"6.42","spread":"15.130"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"7.70","spread":"16.488"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"5.68","spread":"17.332"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"4.74","spread":"19.032"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"6.08","spread":"18.717"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"7.68","spread":"17.992"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"6.41","spread":"18.239"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"7.94","spread":"18.614"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"3.64","spread":"19.866"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"5.48","spread":"18.625"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"6.28","spread":"17.854"}]}]}]},{"type":"SECONDARY","title":"Change From Baseline in EQ-5D-5L VAS, by Visit in Patients From BAT Group Who Cross Over to Ruxolitinib After Crossover","description":"EQ-5D-5L is a standardized instrument for measuring health outcomes in a wide range of health conditions and treatments. It consists of visual analogue scale (EQ VAS) which records the respondent's self-rated health on a vertical, visual analogue scale where the endpoints are labeled 'Best imaginable health state' and 'worst imaginable health state'. The EQ VAS scores were anchored on 100 = the best health you can imagine and 0 = worst health you can imagine.","paramType":"MEAN","dispersionType":"Standard Deviation","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"4.54","spread":"14.756"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"4.62","spread":"15.807"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"6.58","spread":"14.667"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"6.38","spread":"17.564"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"5.26","spread":"15.923"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"4.71","spread":"21.006"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"8.09","spread":"16.119"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"6.48","spread":"18.085"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"4.92","spread":"16.983"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"4.87","spread":"20.047"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"3.19","spread":"17.798"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"2.65","spread":"20.221"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"4.59","spread":"13.731"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"2.71","spread":"19.673"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"5.65","spread":"18.286"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"5.35","spread":"18.099"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"7.71","spread":"16.701"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"5.30","spread":"18.342"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"4.14","spread":"16.427"}]}]}]},{"type":"SECONDARY","title":"Change From Baseline in Work Productivity and Activity Impairment (WPAI) Questionnaire","description":"The Work Productivity and Activity Impairment Questionnaire: Specific Health Problem (WPAI:SHP) is a six item questionnaire which intended to measure work and activity impairment associated with polycythemia vera. WPAI consisted of 6 questions (Q1=Employment status; Q2=Hours absent from work due to the polycythemia vera; Q3=Hours absent from work due to other reasons; Q4=Hours actually worked; Q5=Impact of the polycythemia vera on productivity while working; Q6=Impact of the polycythemia vera on productivity while doing regular daily activities other than work). Higher WPAI scores indicated greater activity impairment. Scores were multiplied by 100 to express in percentages.\n\nPercent work time missed due to problem (past 7 days) =Q2/(Q2+Q4) Percent impairment while working due to problem (past 7 days): Q5/10 Percent overall work impairment due to problem (past 7 says): Q2/(Q2+Q4)+\\[(1 Q2/(Q2+Q4))x(Q5/10)\\] Percent activity impairment due to problem (past 7 says): Q6/10","paramType":"MEAN","dispersionType":"Standard Deviation","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-5.50","spread":"18.425"},{"groupId":"OG001","value":"-0.40","spread":"13.928"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-4.88","spread":"13.381"},{"groupId":"OG001","value":"-4.35","spread":"20.820"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"4.50","spread":"35.948"},{"groupId":"OG001","value":"4.79","spread":"25.917"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-5.85","spread":"17.119"},{"groupId":"OG001","value":"-2.19","spread":"9.852"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-2.82","spread":"30.770"},{"groupId":"OG001","value":"-8.33","spread":"11.785"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"1.87","spread":"34.151"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-6.67","spread":"23.310"},{"groupId":"OG001","value":"0.00","spread":"14.951"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-13.16","spread":"19.164"},{"groupId":"OG001","value":"-0.59","spread":"13.449"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-14.00","spread":"21.374"},{"groupId":"OG001","value":"4.12","spread":"16.977"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-14.29","spread":"23.994"},{"groupId":"OG001","value":"-10.00","spread":"14.142"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-10.00","spread":"23.170"},{"groupId":"OG001","value":"-20.00","spread":"42.426"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-14.76","spread":"26.385"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-9.63","spread":"22.495"},{"groupId":"OG001","value":"-2.34","spread":"14.807"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-11.32","spread":"18.505"},{"groupId":"OG001","value":"-4.38","spread":"17.568"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-10.26","spread":"33.296"},{"groupId":"OG001","value":"5.34","spread":"22.063"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-15.98","spread":"23.077"},{"groupId":"OG001","value":"-8.85","spread":"11.722"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-12.61","spread":"27.576"},{"groupId":"OG001","value":"-22.50","spread":"45.962"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-14.36","spread":"30.691"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-11.97","spread":"22.122"},{"groupId":"OG001","value":"2.42","spread":"24.310"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-11.58","spread":"24.985"},{"groupId":"OG001","value":"1.97","spread":"16.413"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-14.36","spread":"25.222"},{"groupId":"OG001","value":"0.65","spread":"18.980"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-11.67","spread":"25.826"},{"groupId":"OG001","value":"2.73","spread":"23.941"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-11.23","spread":"25.360"},{"groupId":"OG001","value":"0.00","spread":"15.374"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-11.09","spread":"24.166"}]}]}]},{"type":"SECONDARY","title":"Change From Baseline in Work Productivity and Activity Impairment Questionnaire (WPAI), by Visit in Patients From BAT Group Who Cross Over to Ruxolitinib After Crossover","description":"The Work Productivity and Activity Impairment Questionnaire: Specific Health Problem (WPAI:SHP) is a six item questionnaire which intended to measure work and activity impairment associated with polycythemia vera. WPAI consisted of 6 questions (Q1=Employment status; Q2=Hours absent from work due to the polycythemia vera; Q3=Hours absent from work due to other reasons; Q4=Hours actually worked; Q5=Impact of the polycythemia vera on productivity while working; Q6=Impact of the polycythemia vera on productivity while doing regular daily activities other than work). Higher WPAI scores indicated greater activity impairment. Scores were multiplied by 100 to express in percentages.\n\nPercent work time missed due to problem (past 7 days) =Q2/(Q2+Q4) Percent impairment while working due to problem (past 7 days): Q5/10 Percent overall work impairment due to problem (past 7 says): Q2/(Q2+Q4)+\\[(1 Q2/(Q2+Q4))x(Q5/10)\\] Percent activity impairment due to problem (past 7 says): Q6/10","paramType":"MEAN","dispersionType":"Standard Deviation","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-7.45","spread":"28.102"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-3.90","spread":"33.237"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-2.66","spread":"40.422"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-1.67","spread":"5.000"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"7.06","spread":"21.757"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"1.12","spread":"3.175"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-5.33","spread":"9.904"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-4.29","spread":"11.579"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-10.83","spread":"20.207"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-6.92","spread":"13.156"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-3.33","spread":"23.868"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-6.00","spread":"13.499"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-10.98","spread":"20.249"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-6.91","spread":"24.416"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-4.73","spread":"30.167"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-6.06","spread":"14.099"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-1.81","spread":"20.220"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-4.03","spread":"12.712"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-10.43","spread":"19.886"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-8.63","spread":"20.978"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-8.82","spread":"21.877"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-6.47","spread":"25.363"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-6.94","spread":"26.395"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-7.00","spread":"22.781"}]}]}]},{"type":"SECONDARY","title":"Patient Global Impression of Change (PGIC)","description":"The Patient Global Impression of Change (PGIC) is comprised of a single question intended to measure a patient's perspective of improvement or deterioration over time relative to treatment. The PGIC uses a seven-point scale where one (1) equals very much improved and seven (7) equals very much worse.","paramType":"COUNT_OF_PARTICIPANTS","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"10","spread":null},{"groupId":"OG001","value":"0","spread":null}]},{"measurements":[{"groupId":"OG000","value":"22","spread":null},{"groupId":"OG001","value":"8","spread":null}]},{"measurements":[{"groupId":"OG000","value":"21","spread":null},{"groupId":"OG001","value":"7","spread":null}]},{"measurements":[{"groupId":"OG000","value":"14","spread":null},{"groupId":"OG001","value":"50","spread":null}]},{"measurements":[{"groupId":"OG000","value":"1","spread":null},{"groupId":"OG001","value":"6","spread":null}]},{"measurements":[{"groupId":"OG000","value":"0","spread":null},{"groupId":"OG001","value":"0","spread":null}]},{"measurements":[{"groupId":"OG000","value":"0","spread":null},{"groupId":"OG001","value":"1","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"11","spread":null},{"groupId":"OG001","value":"1","spread":null}]},{"measurements":[{"groupId":"OG000","value":"27","spread":null},{"groupId":"OG001","value":"14","spread":null}]},{"measurements":[{"groupId":"OG000","value":"15","spread":null},{"groupId":"OG001","value":"9","spread":null}]},{"measurements":[{"groupId":"OG000","value":"15","spread":null},{"groupId":"OG001","value":"35","spread":null}]},{"measurements":[{"groupId":"OG000","value":"0","spread":null},{"groupId":"OG001","value":"10","spread":null}]},{"measurements":[{"groupId":"OG000","value":"1","spread":null},{"groupId":"OG001","value":"0","spread":null}]},{"measurements":[{"groupId":"OG000","value":"0","spread":null},{"groupId":"OG001","value":"1","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"18","spread":null},{"groupId":"OG001","value":"2","spread":null}]},{"measurements":[{"groupId":"OG000","value":"25","spread":null},{"groupId":"OG001","value":"13","spread":null}]},{"measurements":[{"groupId":"OG000","value":"13","spread":null},{"groupId":"OG001","value":"12","spread":null}]},{"measurements":[{"groupId":"OG000","value":"8","spread":null},{"groupId":"OG001","value":"33","spread":null}]},{"measurements":[{"groupId":"OG000","value":"2","spread":null},{"groupId":"OG001","value":"4","spread":null}]},{"measurements":[{"groupId":"OG000","value":"0","spread":null},{"groupId":"OG001","value":"5","spread":null}]},{"measurements":[{"groupId":"OG000","value":"0","spread":null},{"groupId":"OG001","value":"0","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"19","spread":null},{"groupId":"OG001","value":"0","spread":null}]},{"measurements":[{"groupId":"OG000","value":"25","spread":null},{"groupId":"OG001","value":"4","spread":null}]},{"measurements":[{"groupId":"OG000","value":"12","spread":null},{"groupId":"OG001","value":"5","spread":null}]},{"measurements":[{"groupId":"OG000","value":"9","spread":null},{"groupId":"OG001","value":"15","spread":null}]},{"measurements":[{"groupId":"OG000","value":"1","spread":null},{"groupId":"OG001","value":"3","spread":null}]},{"measurements":[{"groupId":"OG000","value":"0","spread":null},{"groupId":"OG001","value":"0","spread":null}]},{"measurements":[{"groupId":"OG000","value":"0","spread":null},{"groupId":"OG001","value":"0","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"23","spread":null},{"groupId":"OG001","value":"0","spread":null}]},{"measurements":[{"groupId":"OG000","value":"30","spread":null},{"groupId":"OG001","value":"7","spread":null}]},{"measurements":[{"groupId":"OG000","value":"5","spread":null},{"groupId":"OG001","value":"2","spread":null}]},{"measurements":[{"groupId":"OG000","value":"6","spread":null},{"groupId":"OG001","value":"10","spread":null}]},{"measurements":[{"groupId":"OG000","value":"2","spread":null},{"groupId":"OG001","value":"0","spread":null}]},{"measurements":[{"groupId":"OG000","value":"0","spread":null},{"groupId":"OG001","value":"0","spread":null}]},{"measurements":[{"groupId":"OG000","value":"0","spread":null},{"groupId":"OG001","value":"0","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"27","spread":null},{"groupId":"OG001","value":"2","spread":null}]},{"measurements":[{"groupId":"OG000","value":"28","spread":null},{"groupId":"OG001","value":"5","spread":null}]},{"measurements":[{"groupId":"OG000","value":"8","spread":null},{"groupId":"OG001","value":"1","spread":null}]},{"measurements":[{"groupId":"OG000","value":"5","spread":null},{"groupId":"OG001","value":"5","spread":null}]},{"measurements":[{"groupId":"OG000","value":"2","spread":null},{"groupId":"OG001","value":"1","spread":null}]},{"measurements":[{"groupId":"OG000","value":"0","spread":null},{"groupId":"OG001","value":"0","spread":null}]},{"measurements":[{"groupId":"OG000","value":"0","spread":null},{"groupId":"OG001","value":"0","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"23","spread":null},{"groupId":"OG001","value":"1","spread":null}]},{"measurements":[{"groupId":"OG000","value":"31","spread":null},{"groupId":"OG001","value":"1","spread":null}]},{"measurements":[{"groupId":"OG000","value":"6","spread":null},{"groupId":"OG001","value":"3","spread":null}]},{"measurements":[{"groupId":"OG000","value":"6","spread":null},{"groupId":"OG001","value":"0","spread":null}]},{"measurements":[{"groupId":"OG000","value":"1","spread":null},{"groupId":"OG001","value":"0","spread":null}]},{"measurements":[{"groupId":"OG000","value":"0","spread":null},{"groupId":"OG001","value":"0","spread":null}]},{"measurements":[{"groupId":"OG000","value":"0","spread":null},{"groupId":"OG001","value":"0","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"22","spread":null},{"groupId":"OG001","value":"0","spread":null}]},{"measurements":[{"groupId":"OG000","value":"24","spread":null},{"groupId":"OG001","value":"0","spread":null}]},{"measurements":[{"groupId":"OG000","value":"9","spread":null},{"groupId":"OG001","value":"0","spread":null}]},{"measurements":[{"groupId":"OG000","value":"10","spread":null},{"groupId":"OG001","value":"0","spread":null}]},{"measurements":[{"groupId":"OG000","value":"2","spread":null},{"groupId":"OG001","value":"0","spread":null}]},{"measurements":[{"groupId":"OG000","value":"0","spread":null},{"groupId":"OG001","value":"0","spread":null}]},{"measurements":[{"groupId":"OG000","value":"1","spread":null},{"groupId":"OG001","value":"0","spread":null}]}]}]},{"type":"SECONDARY","title":"Summary of Patient Global Impression of Change (PGIC), by Visit in Patients From BAT Group Who Cross Over to Ruxolitinib After Crossover","description":"The Patient Global Impression of Change (PGIC) is comprised of a single question intended to measure a patient's perspective of improvement or deterioration over time relative to treatment. The PGIC uses a seven-point scale where one (1) equals very much improved and seven (7) equals very much worse.","paramType":"COUNT_OF_PARTICIPANTS","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"10","spread":null}]},{"measurements":[{"groupId":"OG000","value":"13","spread":null}]},{"measurements":[{"groupId":"OG000","value":"13","spread":null}]},{"measurements":[{"groupId":"OG000","value":"16","spread":null}]},{"measurements":[{"groupId":"OG000","value":"0","spread":null}]},{"measurements":[{"groupId":"OG000","value":"0","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"11","spread":null}]},{"measurements":[{"groupId":"OG000","value":"25","spread":null}]},{"measurements":[{"groupId":"OG000","value":"9","spread":null}]},{"measurements":[{"groupId":"OG000","value":"7","spread":null}]},{"measurements":[{"groupId":"OG000","value":"1","spread":null}]},{"measurements":[{"groupId":"OG000","value":"0","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"12","spread":null}]},{"measurements":[{"groupId":"OG000","value":"28","spread":null}]},{"measurements":[{"groupId":"OG000","value":"6","spread":null}]},{"measurements":[{"groupId":"OG000","value":"6","spread":null}]},{"measurements":[{"groupId":"OG000","value":"0","spread":null}]},{"measurements":[{"groupId":"OG000","value":"0","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"19","spread":null}]},{"measurements":[{"groupId":"OG000","value":"17","spread":null}]},{"measurements":[{"groupId":"OG000","value":"5","spread":null}]},{"measurements":[{"groupId":"OG000","value":"8","spread":null}]},{"measurements":[{"groupId":"OG000","value":"1","spread":null}]},{"measurements":[{"groupId":"OG000","value":"0","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"18","spread":null}]},{"measurements":[{"groupId":"OG000","value":"19","spread":null}]},{"measurements":[{"groupId":"OG000","value":"6","spread":null}]},{"measurements":[{"groupId":"OG000","value":"6","spread":null}]},{"measurements":[{"groupId":"OG000","value":"1","spread":null}]},{"measurements":[{"groupId":"OG000","value":"0","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"18","spread":null}]},{"measurements":[{"groupId":"OG000","value":"15","spread":null}]},{"measurements":[{"groupId":"OG000","value":"5","spread":null}]},{"measurements":[{"groupId":"OG000","value":"6","spread":null}]},{"measurements":[{"groupId":"OG000","value":"0","spread":null}]},{"measurements":[{"groupId":"OG000","value":"0","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"17","spread":null}]},{"measurements":[{"groupId":"OG000","value":"16","spread":null}]},{"measurements":[{"groupId":"OG000","value":"6","spread":null}]},{"measurements":[{"groupId":"OG000","value":"3","spread":null}]},{"measurements":[{"groupId":"OG000","value":"0","spread":null}]},{"measurements":[{"groupId":"OG000","value":"0","spread":null}]}]}]},{"type":"SECONDARY","title":"Number of Participants Developing Thrombosis","description":"Proportion of participants developing any arterial or venous thromboembolic event","paramType":"COUNT_OF_PARTICIPANTS","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"0","spread":null},{"groupId":"OG001","value":"0","spread":null}]}]}]},{"type":"POST_HOC","title":"Total Number of Deaths","description":"On-treatment deaths were reported from the day of first dose of study medication to the End of study (End of Treatment +30 days) visit which was Week 260 or prior (+30 days for Rux + crossover) and Week 80 or prior (+30 days for BAT only). Post-treatment deaths were reported following completion study treatment (Week 80 for patients receiving BAT, or Week 260 for patients receiving ruxolitinib) or from the time of premature discontinuation. Patients were followed for survival every three months up to end of study.","paramType":"NUMBER","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"1","spread":null},{"groupId":"OG001","value":"1","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0","spread":null},{"groupId":"OG001","value":"3","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"2","spread":null},{"groupId":"OG001","value":"2","spread":null}]}]}]}],"adverseEventsModule":{"adverseEventsSummary":{"seriousAny":{"events":34,"n":74},"commonTop":["Anaemia","Pruritus","Headache","Weight increased","Arthralgia"]}}}